Richman Michael 4

What Happened

• Michael Richman, President & CEO and Director of NextCure, was granted 38,190 derivative shares (reported as an award) on January 30, 2026. The filing shows an acquisition price of $0 (no cash paid) and records the transaction as a derivative award (Form 4 code A). This is a compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-30 (filed 2026-02-03; filing is within the required 2 business days)
• Security: 38,190 derivative shares reported as an award (code A)
• Reported price/proceeds: $0 (no cash paid at grant)
• Shares owned after transaction: Not disclosed in this filing
• Footnote: Vesting—one-fourth vests on Jan 30, 2027; the remainder vests in 36 monthly installments beginning Feb 28, 2027
• No indication of a 10b5-1 plan, cashless sale, gift, or tax-withholding in this filing

Context

• This was a time‑based compensation award (derivative securities) that vests over multiple years. Such grants are common for executives as retention/compensation and do not by themselves indicate an immediate market move (no shares were sold or purchased on the open market).